Published Date : Sep 19, 2016
ALBANY, NY, Sep 19, 2016 - MarketResearchReports.biz has added a new report, titled “Osteoporosis Therapeutics In Asia-Pacific Markets To 2022 - Growth Driven By Rising Prevalence, Growing Awareness And Expected Launch Of Anabolic Therapies,” to its offering.
This study presents an in-depth evaluation of the market and comprises the key opportunities in osteoporosis therapeutics in Asia-Pacific markets. The prime drivers and impeders impacting the development of this market have also been presented through this study. The report also helps in understanding the commercial and current clinical landscape by the consideration of diagnosis, disease pathogenesis, treatment options, and prognosis related to osteoporosis.
The first section of the study presents the disease introduction, diagnosis, and treatment options for osteoporosis. The current size and the predicted size of this market in Asia Pacific markets has also been presented in this section of the study. The Asia Pacific osteoporosis market stood at $4.5 bn in 2015 and is predicted to touch $7.7 bn in 2022, expanding at a CAGR of 7.80% from 2015 to 2022. The treatment options utilized including treatment algorithm, pharmacological treatments, and non-pharmacological treatments have also been encapsulated under this part of the study. Osteoporosis refers to prevalent metabolic bone disease and accompanies an increased risk of fracture caused due to micro architectural worsening of bone tissue and low bone mass.
In the next section, the top marketed products in osteoporosis therapeutics in Asia-Pacific markets have been presented. This section also comprise a broad range of treatment options for osteoporosis such as bisphosphonates, RANKL inhibitors, SERMs, a dual-action non-bisphosphonate (strontium ranelate), PTH analogues, and calcitonins. Amongst these, SERMs and bisphosphonate lead the osteoporosis therapeutics in Asia-Pacific markets at present.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/784620
Moving further, sections on pipeline reports and clinical trial reports have been presented. These sections encapsulate the most lucrative pipeline candidates such as Abaloparatide-SC (BA-058-SC) - Radius Health, Odanacatib (MK-0822) - Merck & Co, and Uni-PTH - Uni-Bio. In the following part of the study, the geographical segmentation of the market has been presented. By country, the report categorizes the market into Japan, South Korea, Australia, China, and India. The size of the market, the annual cost of therapy, and the treatment utilization patterns for osteoporosis in all these nations have been presented in detail.
The dynamics impacting the development of the market come next in the report. The increasing occurrence of osteoporosis and the rising health insurance coverage for aging population in Asia Pacific are amongst the chief factors providing impetus to the development of osteoporosis therapeutics in Asia-Pacific markets. In addition, the introduction of lucrative late-stage pipeline products have brought in new growth opportunities in this market. On the other hand, the increasing competition from conventional medicines and low diagnosis of osteoporosis may negatively impact the development of osteoporosis therapeutics in Asia Pacific markets.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org